背景:尽管数百项药物的临床试验最初显示出希望,阿尔茨海默病(AD)的临床改善有限。这可能归因于存在至少25种作为该疾病基础的异常细胞途径。单一药物不可能解决所有或大多数这些途径,因此,即使单独给药时显示出希望的药物也不太可能产生显著的结果。根据以前的研究,八种药物,即,丹曲林,促红细胞生成素,锂,美金刚,米诺环素,吡拉西坦,利鲁唑,和水飞蓟素,已发现靶向参与AD发展的多种途径。在这些药物中,利鲁唑目前被用于治疗成人患者和儿童的医疗状况,并且由于其在神经退行性疾病的兴奋毒性假说中的潜力而获得了科学家的越来越多的关注。
目的:本研究的目的是基于细胞和分子机制研究药物对AD的影响。
方法:本研究的文献检索利用Scopus,ScienceDirect,PubMed,和谷歌学术数据库来识别相关文章。
结果:利鲁唑通过多种途径发挥其在AD中的作用,包括抑制电压依赖性钠和钙通道,阻断AMPA和NMDA受体,抑制谷氨酸释放和刺激EAAT1-EAAT2。
结论:在这篇综述文章中,我们的目的是回顾利鲁唑的神经保护特性,谷氨酸调节剂,在AD中,这可以使患有这种疾病的患者受益。
BACKGROUND: Despite several hundred clinical trials of drugs that initially showed promise, there has been limited clinical improvement in Alzheimer\'s disease (AD). This may be attributed to the existence of at least 25 abnormal cellular pathways that underlie the disease. It is improbable for a single drug to address all or most of these pathways, thus even drugs that show promise when administered alone are unlikely to produce significant results. According to previous studies, eight drugs, namely, dantrolene, erythropoietin, lithium, memantine, minocycline, piracetam, riluzole, and silymarin, have been found to target multiple pathways that are involved in the development of AD. Among these drugs, riluzole is currently indicated for the treatment of medical conditions in both adult patients and children and has gained increased attention from scientists due to its potential in the excitotoxic hypothesis of neurodegenerative diseases.
OBJECTIVE: The aim of this study was to investigate the effects of drugs on AD based on cellular and molecular mechanisms.
METHODS: The literature search for this study utilized the Scopus, ScienceDirect, PubMed, and Google Scholar databases to identify relevant articles.
RESULTS: Riluzole exerts its effects in AD through diverse pathways including the inhibition of voltage-dependent sodium and calcium channels, blocking AMPA and NMDA receptors and inhibiting the release of glutamic acid release and stimulation of EAAT1-EAAT2.
CONCLUSIONS: In this
review article, we aimed to
review the neuroprotective properties of riluzole, a glutamate modulator, in AD, which could benefit patients with the disease.